Cognito Therapeutics, a medical device company using light and sound to treat neurodegenerative disease, raised a $35 million Series B extension.
Why it matters: Cognito bills its product as a noninvasive, less costly alternative to Alzheimer's drugs, but the company will have to prove that in the clinic.
